fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Ciprofloxacin

All products: Limited Use (codes 533)

Cipro · DIN 02237514 · 10 g/100 mL · Oral suspension

Limited Use, Reason for Use code 533 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 533 required
Write on scriptReason for Use code 533 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 533
Reason for Use code 533 For patients who are unable to swallow or tolerate solid oral dosage forms. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Cipro · DIN 02237514 Manufacturer: Bayer Inc., Consumer Care Division; listing date 2001-03-07 Daily cost (source): $5.7560 Health Canada: Marketed since 1998-09-15 · brand CIPRO ORAL SUSPENSION · ATC J01MA02 CIPROFLOXACIN · form Suspension · route Oral · ingredients CIPROFLOXACIN 500 MG/5ML · company Bayer inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Cipro: Formulary list price $0.58 per unit (the source does not state the unit; exact figure $0.5756). What the ministry pays, not the patient.

Ministry pays: $0.5756 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02237514)

Source record
DIN 02237514: Cipro Raw flags: sec12=Y, sec3=Y Item: 084000050; group id 130; item number 0219; lccId 00307; manufacturer id BAY Source form: Oral Susp; strength: 10g/100mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.5756; ministry $0.5756 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02237514 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60849
Shortage status: anticipated shortage (last updated September 18, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02237514
Shortage record checked October 6, 2026

Other products in the same Health Canada class (J01MA): coverage varies; not interchangeable

  • Levofloxacin (Levaquin): general benefit, not a benefit
  • Moxifloxacin (Avelox): general benefit, not a benefit
  • Norfloxacin (Noroxin): general benefit, not a benefit
  • Ciprofloxacin + ciprofloxacin base (Cipro XL): limited Use 394, not a benefit
Other drugs in the same formulary class (08:40 Miscellaneous Anti-Infectives) and how they are covered

Matched class: 08:40 Miscellaneous Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): LEVOFLOXACIN, MOXIFLOXACIN HYDROCHLORIDE, NORFLOXACIN, SULFAMETHOXAZOLE & TRIMETHOPRIM, TRIMETHOPRIM 08:40 Miscellaneous Anti-Infectives

LEVOFLOXACIN

· 24 products · Listed, not a benefit (2), General benefit (14), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 250mg, 500mg, 750mg · Tab

MOXIFLOXACIN HYDROCHLORIDE

· 12 products · Listed, not a benefit (1), General benefit (11) · strengths: 400mg · Tab

NORFLOXACIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 400mg · Tab

CIPROFLOXACIN HCL & CIPROFLOXACIN BASE

· 2 products · Listed, not a benefit (1), Limited Use, codes 394 (1) · strengths: 500mg · ER Tab

SULFAMETHOXAZOLE & TRIMETHOPRIM

· 9 products · Listed, not a benefit (6), General benefit (3) · strengths: 40mg & 8mg/mL, 400mg & 80mg, 800mg & 160mg · O/L, Tab

TRIMETHOPRIM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mg, 200mg · Tab

LINEZOLID

· 7 products · Off-Formulary Interchangeable, not an ODB benefit (3), Listed, not a benefit (1), Limited Use, codes 362, 363, 364 (3) · strengths: 2mg/mL, 600mg · Inj-300mL Pk, Tab

CEFEPIME

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g, 2g · Inj Pd-Vial Pk

ERTAPENEM

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial · Inj Pd-Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:40
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE CILOXAN® (ciprofloxacin ophthalmic solution) is indicated for the treatment of the following infections of the eye and its adnexae when caused by susceptible strains of the designated bacteria. Corneal Ulcers: Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae. Conjunctivitis: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus (Viridans group), Streptococcus pneumoniae, Haemophilus influenzae. CILOXAN® (ciprofloxacin ophthalmic ointment) is indicated for the treatment of the following infections of the eye and its adnexae when caused by susceptible strains of the designated bacteria. Corneal Ulcers: Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis. Conjunctivitis: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus (Viridans group), Streptococcus pneumoniae, Haemophilus influenzae. To reduce the development of drug-resistant bacteria and maintain the effectiveness of CILOXAN and other antibac… https://pdf.hres.ca/dpd_pm/00045906.PDF PM date: May 22, 2018 Source product: CILOXAN; DIN 01945270; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.